Unigene Ends China Peptide JV; Will Out-License Technology

Unigene Laboratories, a US company that develops and makes peptide-based drugs, has closed out an eleven-year-old China JV. Unigene owned a 45% stake in Unigene Biotechnology Co., Ltd., which it will sell to its partner China Pharmaceutical Group Limited for $1 million, the amount of its original investment. In Q1 of 2011, Unigene recorded a $300,000 loss from the JV. More details.... Stock Symbol: (OTCBB: UGNE)